|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis.
|
20081802 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
1p19q whole loss was also significantly associated with Olig2 overexpression, but was never observed in tumors overexpressing p53 protein.
|
20081802 |
2010 |
|
Down Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
BHLHB1 mapped to the region of chromosome 21 that has been proposed to be responsible, at least in part, for the learning deficits seen in children with Down's syndrome.
|
10737801 |
2000 |
|
Complete Trisomy 21 Syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
BHLHB1 mapped to the region of chromosome 21 that has been proposed to be responsible, at least in part, for the learning deficits seen in children with Down's syndrome.
|
10737801 |
2000 |
|
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
OLIG2-positive cells corresponding to neoplastic oligodendrocytes were present in all oligodendrogliomas and oligoastrocytomas.
|
11498220 |
2001 |
|
Well Differentiated Oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
OLIG2-positive cells corresponding to neoplastic oligodendrocytes were present in all oligodendrogliomas and oligoastrocytomas.
|
11498220 |
2001 |
|
Brain Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
OLIG2 protein expression is present but inconsistent and generally lower in most other brain tumors and is absent in non-neuroectodermal tumors.
|
15198128 |
2004 |
|
Neuroectodermal Tumors
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
OLIG2 protein expression is present but inconsistent and generally lower in most other brain tumors and is absent in non-neuroectodermal tumors.
|
15198128 |
2004 |
|
Leukemogenesis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.
|
16103065 |
2005 |
|
Central Nervous System Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms.
|
17257132 |
2007 |
|
Brain Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
|
18552083 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
|
21193945 |
2011 |
|
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
|
Well Differentiated Oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
|
Neoplasms, Neuroepithelial
|
0.010 |
Biomarker
|
group |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
|
Pilocytic Astrocytoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
|
Pituicytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Olig2 was only positive in 1 pituicytoma.
|
23887161 |
2013 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
OLIG2, a proliferation regulator and glioma progenitor cell marker upregulated in IGCs was found to function in enhancing migration and stemness of GSCs.
|
25365423 |
2014 |
|
Astrocytoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Olig2 was positive in 5 out of 44 ependymomas (11%) and 50 out of 54 (93%) non-ependymal tumors (astrocytomas and oligodendrogliomas).
|
26287936 |
2016 |
|
oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig2 was positive in 5 out of 44 ependymomas (11%) and 50 out of 54 (93%) non-ependymal tumors (astrocytomas and oligodendrogliomas).
|
26287936 |
2016 |
|
Well Differentiated Oligodendroglioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig2 was positive in 5 out of 44 ependymomas (11%) and 50 out of 54 (93%) non-ependymal tumors (astrocytomas and oligodendrogliomas).
|
26287936 |
2016 |
|
Malignant Glioma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.
|
27165742 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Olig2 deletion causes a tumor phenotypic shift from an oligodendrocyte precursor-correlated proneural toward an astroglia-associated gene expression pattern, manifest in downregulation of platelet-derived growth factor receptor-α and reciprocal upregulation of epidermal growth factor receptor (EGFR).
|
27165742 |
2016 |